首页> 外文期刊>Radiation oncology >Evaluation of inter- and intrafractional motion of liver tumors using interstitial markers and implantable electromagnetic radiotransmitters in the context of image-guided radiotherapy (IGRT) – the ESMERALDA trial
【24h】

Evaluation of inter- and intrafractional motion of liver tumors using interstitial markers and implantable electromagnetic radiotransmitters in the context of image-guided radiotherapy (IGRT) – the ESMERALDA trial

机译:在影像引导放射治疗(IGRT)的背景下,使用组织间标记物和可植入的电磁辐射发射器评估肝肿瘤的分数内和分数内运动– ESMERALDA试验

获取原文
           

摘要

Background With the development of more conformal and precise radiation techniques such as Intensity-Modulated Radiotherapy (IMRT), Stereotactic Body Radiotherapy (SBRT) and Image-Guided Radiotherapy (IGRT), patients with hepatic tumors could be treated with high local doses by sparing normal liver tissue. However, frequently occurring large HCC tumors are still a dosimetric challenge in spite of modern high sophisticated RT modalities. This interventional clinical study has been set up to evaluate the value of different fiducial markers, and to use the modern imaging methods for further treatment optimization using physical and informatics approaches. Methods and design Surgically implanted radioopaque or electromagnetic markers are used to detect tumor local-ization during radiotherapy. The required markers for targeting and observation during RT can be implanted in a previously defined optimal position during the oncologically indicated operation. If there is no indication for a surgical resection or open biopsy, markers may be inserted into the liver or tumor tissue by using ultrasound-guidance. Primary study aim is the detection of the patients′ anatomy at the time of RT by observation of the marker position during the indicated irradiation (IGRT). Secondary study aims comprise detection and recording of 3D liver and tumor motion during RT. Furthermore, the study will help to develop technical strategies and mechanisms based on the recorded information on organ motion to avoid inaccurate dose application resulting from fast organ motion and deformation. Discussion This is an open monocentric non-randomized, prospective study for the evaluation of organ motion using interstitial markers or implantable radiotransmitter. The trial will evaluate the full potential of different fiducial markers to further optimize treatment of moving targets, with a special focus on liver lesions.
机译:背景技术随着强度调节放射疗法(IMRT),立体定向放射疗法(SBRT)和影像引导放射疗法(IGRT)等保形和精确放射技术的发展,肝肿瘤患者可以通过保留正常剂量接受高局部剂量治疗肝组织。然而,尽管具有现代高度复杂的RT方法,但经常发生的大型HCC肿瘤仍是剂量学挑战。已经建立了这项介入性临床研究,以评估不同基准标记的价值,并使用现代成像方法通过物理和信息学方法进一步优化治疗。方法和设计手术植入的不透射线或电磁标记物可用于检测放疗期间的肿瘤定位。在肿瘤学指示的手术过程中,可以将RT期间用于靶向和观察所需的标记物植入先前定义的最佳位置。如果没有手术切除或活检的迹象,可通过超声引导将标记物插入肝脏或肿瘤组织。主要研究目的是通过观察指示照射(IGRT)期间的标志物位置,在RT时检测患者的解剖结构。次级研究的目的包括在RT期间检测和记录3D肝脏和肿瘤运动。此外,该研究将有助于根据所记录的器官运动信息来开发技术策略和机制,以避免因器官快速运动和变形而导致剂量应用不准确。讨论这是一项开放性的单中心,非随机,前瞻性研究,用于使用组织间标记物或可植入的无线电发射器评估器官运动。该试验将评估不同基准标记物的潜力,以进一步优化移动靶标的治疗,并特别关注肝脏病变。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号